Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Blase

Showing results (451-460 of 466) with videos related to

Pageof 47
Sort By:
Cancer Discovery|November 25, 2020
Personalized Antibodies for Gastroesophageal Adenocarcinoma (PANGEA): A Phase II Study Evaluating an Individualized Treatment Strategy for Metastatic DiseaseDaniel V T Catenacci, Stephanie Moya, Samantha Lomnicki, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 25, 2021
Phase I Study of Stereotactic Body Radiotherapy plus Nivolumab and Urelumab or Cabiralizumab in Advanced Solid TumorsCorey C Foster, Gini F Fleming, Theodore G Karrison, et al.
JNCI Cancer Spectrum|January 11, 2021
IGF-Binding Proteins, Adiponectin, and Survival in Metastatic Colorectal Cancer: Results From CALGB (Alliance)/SWOG 80405Brendan J Guercio, Sui Zhang, Fang-Shu Ou, et al.
JAMA Network Open|January 9, 2024
Organ Preservation and Survival by Clinical Response Grade in Patients With Rectal Cancer Treated With Total Neoadjuvant Therapy: A Secondary Analysis of the OPRA Randomized Clinical TrialHannah M Thompson, Dana M Omer, Sabrina Lin, et al.
The Lancet. Oncology|February 23, 2017
Nivolumab for previously treated unresectable metastatic anal cancer (NCI9673): a multicentre, single-arm, phase 2 studyVan K Morris, Mohamed E Salem, Halla Nimeiri, et al.
JAMA Network Open|February 15, 2020
Evaluation of the Association of Perioperative UGT1A1 Genotype-Dosed gFOLFIRINOX With Margin-Negative Resection Rates and Pathologic Response Grades Among Patients With Locally Advanced Gastroesophageal Adenocarcinoma: A Phase 2 Clinical TrialDaniel V T Catenacci, Leah Chase, Samantha Lomnicki, et al.
Science Translational Medicine|August 5, 2011
Urine TMPRSS2:ERG fusion transcript stratifies prostate cancer risk in men with elevated serum PSAScott A Tomlins, Sheila M J Aubin, Javed Siddiqui, et al.
Ebiomedicine|September 25, 2024
Crowd-sourced machine learning prediction of long COVID using data from the National COVID Cohort CollaborativeTimothy Bergquist, Johanna Loomba, Emily Pfaff, et al.
Annals of Surgery|August 7, 2025
Real-world Monitoring of ctDNA Reliably Predicts Cancer Recurrence and Treatment Efficacy in Patients with Resected Stages I-III Colon CancerStacey A Cohen, Vasily N Aushev, George Laliotis, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 28, 2022
Organ Preservation in Patients With Rectal Adenocarcinoma Treated With Total Neoadjuvant TherapyJulio Garcia-Aguilar, Sujata Patil, Marc J Gollub, et al.
Pageof 47

Showing results (451-460 of 466) with videos related to

Sort By:
Pageof 47
Cancer Discovery|November 25, 2020
Personalized Antibodies for Gastroesophageal Adenocarcinoma (PANGEA): A Phase II Study Evaluating an Individualized Treatment Strategy for Metastatic DiseaseDaniel V T Catenacci, Stephanie Moya, Samantha Lomnicki, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 25, 2021
Phase I Study of Stereotactic Body Radiotherapy plus Nivolumab and Urelumab or Cabiralizumab in Advanced Solid TumorsCorey C Foster, Gini F Fleming, Theodore G Karrison, et al.
JNCI Cancer Spectrum|January 11, 2021
IGF-Binding Proteins, Adiponectin, and Survival in Metastatic Colorectal Cancer: Results From CALGB (Alliance)/SWOG 80405Brendan J Guercio, Sui Zhang, Fang-Shu Ou, et al.
JAMA Network Open|January 9, 2024
Organ Preservation and Survival by Clinical Response Grade in Patients With Rectal Cancer Treated With Total Neoadjuvant Therapy: A Secondary Analysis of the OPRA Randomized Clinical TrialHannah M Thompson, Dana M Omer, Sabrina Lin, et al.
The Lancet. Oncology|February 23, 2017
Nivolumab for previously treated unresectable metastatic anal cancer (NCI9673): a multicentre, single-arm, phase 2 studyVan K Morris, Mohamed E Salem, Halla Nimeiri, et al.
JAMA Network Open|February 15, 2020
Evaluation of the Association of Perioperative UGT1A1 Genotype-Dosed gFOLFIRINOX With Margin-Negative Resection Rates and Pathologic Response Grades Among Patients With Locally Advanced Gastroesophageal Adenocarcinoma: A Phase 2 Clinical TrialDaniel V T Catenacci, Leah Chase, Samantha Lomnicki, et al.
Science Translational Medicine|August 5, 2011
Urine TMPRSS2:ERG fusion transcript stratifies prostate cancer risk in men with elevated serum PSAScott A Tomlins, Sheila M J Aubin, Javed Siddiqui, et al.
Ebiomedicine|September 25, 2024
Crowd-sourced machine learning prediction of long COVID using data from the National COVID Cohort CollaborativeTimothy Bergquist, Johanna Loomba, Emily Pfaff, et al.
Annals of Surgery|August 7, 2025
Real-world Monitoring of ctDNA Reliably Predicts Cancer Recurrence and Treatment Efficacy in Patients with Resected Stages I-III Colon CancerStacey A Cohen, Vasily N Aushev, George Laliotis, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 28, 2022
Organ Preservation in Patients With Rectal Adenocarcinoma Treated With Total Neoadjuvant TherapyJulio Garcia-Aguilar, Sujata Patil, Marc J Gollub, et al.
Pageof 47